Radek Kucera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3707100/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. American Journal of Transplantation, 2022, 22, 801-812.	4.7	40
2	The coincidence of low vitamin K status and high expression of growth differentiation factor 15 may indicate increased mortality risk in stable coronary heart disease patients. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 540-551.	2.6	6
3	Prognostic Factors After Surgical Treatment of Liver Metastases from Breast Cancer – 19 Years of Experience. In Vivo, 2021, 35, 417-422.	1.3	1
4	Risk of Postoperative Bleeding in Tonsillectomy for Peritonsillar Abscess, as Opposed to in Recurrent and Chronic Tonsillitis—A Retrospective Study. International Journal of Environmental Research and Public Health, 2021, 18, 1946.	2.6	6
5	Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test. Diagnostics, 2021, 11, 593.	2.6	24
6	Prostate Cancer Diagnostic Algorithm as a "Road Map―from the First Stratification of the Patient to the Final Treatment Decision. Life, 2021, 11, 324.	2.4	3
7	The potential of miR-499 plasmatic level as a biomarker ofÂobstructive sleep apnea syndrome. Biomarkers in Medicine, 2021, 15, 1011-1019.	1.4	9
8	The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors. Anticancer Research, 2021, 41, 5117-5122.	1.1	0
9	The Use of CT Pattern in Differentiating Non-invasive, Minimally Invasive and Invasive Variants of Lung Adenocarcinoma. Anticancer Research, 2021, 41, 4479-4482.	1.1	1
10	Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients. Biomarkers in Medicine, 2021, 15, 1465-1477.	1.4	1
11	Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection. Diagnostics, 2021, 11, 1915.	2.6	1
12	A Comparison of ¹⁸ F-FDG-PET/MRI and ¹⁸ F-FDG-PET/CT in the Cancer Staging of Locoregional Lymph Nodes. In Vivo, 2020, 34, 2029-2032.	1.3	2
13	Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies. Cancers, 2020, 12, 2988.	3.7	16
14	The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases. Cancers, 2020, 12, 2434.	3.7	19
15	10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) MedicineÂ- EPMA World Congress Supplement 2020. EPMA Journal, 2020, 11, 1-133.	6.1	34
16	Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer. Cancer Genomics and Proteomics, 2020, 17, 605-613.	2.0	6
17	Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer. BMC Urology, 2020, 20, 144.	1.4	4
18	Outcomes and Prognostic Factors Following Surgical Treatment of Pulmonary Metastases from Colorectal Carcinoma. Anticancer Research, 2020, 40, 7045-7051.	1.1	1

RADEK KUCERA

#	Article	IF	CITATIONS
19	Synergistic effect of sclerostin and angiotensin II receptor 1 polymorphism on arterial stiffening. Biomarkers in Medicine, 2020, 14, 173-184.	1.4	1
20	Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. Anticancer Research, 2020, 40, 1219-1227.	1.1	26
21	Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions. EPMA Journal, 2020, 11, 399-418.	6.1	58
22	Epidemiological and Microbiological Aspects of the Peritonsillar Abscess. International Journal of Environmental Research and Public Health, 2020, 17, 4020.	2.6	17
23	Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients. Cancers, 2019, 11, 864.	3.7	31
24	Informed Consent in the Newly Established Biobank. International Journal of Environmental Research and Public Health, 2019, 16, 3943.	2.6	3
25	The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. Anticancer Research, 2019, 39, 5645-5652.	1.1	9
26	Pretreatment Serum Levels of Soluble Cytokeratin Fragments (Cyfra 21-1, TPS, MonoTotal) in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas. Anticancer Research, 2019, 39, 5171-5177.	1.1	0
27	Blood biomarker panel recommended for personalized prediction, prognosis, and prevention of complications associated with abdominal aortic aneurysm. EPMA Journal, 2019, 10, 125-135.	6.1	12
28	Abdominal aortic aneurysm in prostate cancer patients: the "road map―from incidental detection to advanced predictive, preventive, and personalized approach utilizing common follow-up for both pathologies. EPMA Journal, 2019, 10, 415-423.	6.1	8
29	Oneâ€step nucleic acid amplification vs ultrastaging in the detection of sentinel lymph node metastasis in endometrial cancer patients. Journal of Surgical Oncology, 2019, 119, 361-369.	1.7	29
30	Improved prediction of CPAP failure using T90, age and gender. Journal of Applied Biomedicine, 2019, 17, 81-81.	1.7	3
31	The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. Journal of Cancer, 2018, 9, 4255-4262.	2.5	2
32	An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis. Technology in Cancer Research and Treatment, 2018, 17, 153303381880746.	1.9	2
33	PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma – A Pilot Study. In Vivo, 2018, 32, 1551-1554.	1.3	21
34	Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases. Anticancer Research, 2018, 38, 5531-5537.	1.1	7
35	OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma. Anticancer Research, 2018, 38, 4907-4911.	1.1	10
36	The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6—A Study on 320 Patients After Radical Prostatectomy. Technology in Cancer Research and Treatment, 2018, 17, 153303381878737.	1.9	15

RADEK KUCERA

#	Article	IF	CITATIONS
37	Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases. Anticancer Research, 2018, 38, 3647-3652.	1.1	4
38	CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer. Anticancer Research, 2018, 38, 465-469.	1.1	9
39	Risk factors for failure of continuous positive airway pressure treatment in patients with ostructive sleep apnoea. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2018, 162, 134-138.	0.6	8
40	MIC1/GDF15 as a Bone Metastatic Disease Biomarker. Anticancer Research, 2017, 37, 1501-1506.	1.1	22
41	Serum Levels of IGF-1 and IGFBP-3 in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas. Anticancer Research, 2017, 37, 3281-3286.	1.1	3
42	Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC. Anticancer Research, 2017, 37, 6469-6476.	1.1	11
43	Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. International Journal of Oncology, 2016, 48, 2693-2703.	3.3	20
44	Effect of long-term using of hormonal contraception on anti-Müllerian hormone secretion. Gynecological Endocrinology, 2016, 32, 383-385.	1.7	18
45	Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. Anticancer Research, 2016, 36, 447-53.	1.1	2
46	Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. Anticancer Research, 2016, 36, 455-60.	1.1	9
47	Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. Anticancer Research, 2016, 36, 461-6.	1.1	6
48	The Role of TPS and TPA in the Diagnostics of Distant Metastases. Anticancer Research, 2016, 36, 773-7.	1.1	9
49	Searching for New Biomarkers and the Use of Multivariate Analysis in Gastric Cancer Diagnostics. Anticancer Research, 2016, 36, 1967-71.	1.1	7
50	Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study. Anticancer Research, 2016, 36, 1973-8.	1.1	13
51	Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. Anticancer Research, 2016, 36, 2459-65.	1.1	13
52	Circulating Growth and Angiogenic Factors and Lymph Node Status in Early-stage Breast Cancer - A Pilot Study. Anticancer Research, 2016, 36, 4209-14.	1.1	6
53	Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic. Clinica Chimica Acta, 2015, 444, 271-277.	1.1	18
54	Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics. Anticancer Research, 2015, 35, 3537-41.	1.1	18

#	Article	IF	CITATIONS
55	Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects. Anticancer Research, 2014, 34, 5217-20.	1.1	17